Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

Bailey B. Banach, Gabriele Cerutti, Ahmed S. Fahad, Chen Hsiang Shen, Matheus Oliveira De Souza, Phinikoula S. Katsamba, Yaroslav Tsybovsky, Pengfei Wang, Manoj S. Nair, Yaoxing Huang, Irene M. Francino-Urdániz, Paul J. Steiner, Matías Gutiérrez-González, Lihong Liu, Sheila N. López Acevedo, Alexandra F. Nazzari, Jacy R. Wolfe, Yang Luo, Adam S. Olia, I. Ting TengJian Yu, Tongqing Zhou, Eswar R. Reddem, Jude Bimela, Xiaoli Pan, Bharat Madan, Amy D. Laflin, Rajani Nimrania, Kwok Yung Yuen, Timothy A. Whitehead, David D. Ho, Peter D. Kwong, Lawrence Shapiro, Brandon J. DeKosky

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member of a public antibody response encoded by IGHV3-53/IGHV3-66 genes. Sequence and structural analyses of 910-30 and related antibodies explore how class recognition features correlate with SARS-CoV-2 neutralization. Cryo-EM structures of 910-30 bound to the SARS-CoV-2 spike trimer reveal binding interactions and its ability to disassemble spike. Despite heavy-chain sequence similarity, biophysical analyses of IGHV3-53/3-66-encoded antibodies highlight the importance of native heavy:light pairings for ACE2-binding competition and SARS-CoV-2 neutralization. We develop paired heavy:light class sequence signatures and determine antibody precursor prevalence to be ∼1 in 44,000 human B cells, consistent with public antibody identification in several convalescent COVID-19 patients. These class signatures reveal genetic, structural, and functional immune features that are helpful in accelerating antibody-based medical interventions for SARS-CoV-2.

Original languageEnglish
Article number109771
JournalCell Reports
Volume37
Issue number1
DOIs
Publication statusPublished - Oct 5 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

ASJC Scopus Subject Areas

  • General Biochemistry,Genetics and Molecular Biology

Keywords

  • B-cell
  • SARS-CoV-2
  • biotechnology
  • immunity
  • neutralization
  • public antibody
  • virology
  • yeast display

Cite this